Welcome To The Pharmacogenomic Working Group
The Industry Pharmacogenomics Working Group (I-PWG) is an association of pharmaceutical and biotech companies who are actively engaged in the field of pharmacogenomic (PGx) research.
Who We Are
The Industry-Pharmacogenomics Working Group (I-PWG) is an association of pharmaceutical and biotech companies who are actively engaged in the field of pharmacogenomic (PGx) research. The group’s activities focus on the sharing of non-competitive information in the areas of pharmacogenomic science (and associated technologies), education, ethics, legal, policy and regulatory topics. The group provides information and expert opinion on these topics to increase awareness and understanding of the importance of pharmacogenomic (PGx) and other biomarker research.
A key focus for the I-PWG is to provide a forum for industry leaders working in this field to exchange and share information with the hope of advancing science and enabling better patient outcomes. The group has a number of sub-teams that are actively engaged in topics important for integrating PGx/biomarker research into the drug development process.
Our Mission
To support the integration of pharmacogenomics in patient care and drug development. Our diverse membership is made up of those engaging in regulatory, statistical, technological, genomic and biological research as well as operations. We engage pre-competitively to address emerging issues related to pharmacogenomics.
Our Scope
We focus on topics including, but not limited to genomic technologies, informed consent and ethics,
global regulations and policy, innovative clinical trial design, genomic sample collection and use,
pharmacogenomic biomarkers, patient stratification, pharmacogenomic education, & regulatory use of
genomic data to support drug label statements.
Active Task Forces and Working Groups
The I-PWG is leading the discussion in several key areas related to industry-focused pharmacogenomic
research. It does this through the establishment of a variety of Task Forces and Working Groups that are primarily focused in the areas of ADME, genetics, regulatory science, education and communication, the return of results to clinical trial patients and other emerging areas of scientific interest in the field of pharmacogenomics.
The I-PWG Education Task Force was initiated to develop educational materials for investigators and IRBs/IECs
in order to optimize and streamline the implementation of pharmacogenomics in clinical trials.
Pharmacogenomics in drug development - Impact, Facilitate and Educate!
Play Video
Watch The Full Video
Our Member Companies
What Are The Goals of Pharmacogenomics Research?
Powerful medicines
Pharmaceutical companies can produce targeted therapies for specific diseases which maximize healing effects and reduce damage to healthy cells.
Safe medication
Pharmacogenomics is a branch that aims at developing safe medication and effective doses according to the genetic makeup of an individual.
Advanced disease screening
Improved knowledge of a specific disease allows for careful monitoring and advanced treatment at the earliest.
DNA Collection Survey
The Industry Pharmacogenomics Working Group
(I-PWG) was established in 2000 and is
comprised of functionally diverse members
from pharmaceutical and as well as operations.
We to address emerging issues.
Active Task Forces
The I-PWG is leading the discussion in a number of key areas related to industry-focused pharmacogenomic research. It does this through the establishment of a variety of active Task Forces and Working Groups that are primarily focused in the areas of ADME genetics, regulatory science, education and communication, the return of results to clinical trial patients and other emerging areas of scientific interest in the field of pharmacogenomics.
The I-PWG Education Task Force was initiated to develop educational materials for investigators and IRBs/IECs
in order to optimize and streamline the implementation of pharmacogenomics in clinical trials.
Education & Communication
It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.
Members
- Merck
- Lilly
- Pfizer
Regulatory
The Regulatory Task Force focuses on understanding the global regulatory landscape and the impact it has on the ability to conduct PGx and other biomarker research in drug development. The group accomplishes this through activities that include, but are not limited to, investigating regulatory issues the industry faces via company surveys, reviewing and authoring publications that dive into the impact of country regulations on PGx and biomarker research, and gathering global information across the landscape to provide information for companies to improve their research capabilities.
Members
- Merck
- Lilly
- Pfizer
ADME
It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.
Members
- Merck
- Lilly
- Pfizer